CKD 349
Alternative Names: CKD-349Latest Information Update: 21 Oct 2022
At a glance
- Originator Chong Kun Dang
- Class Heart failure therapies; Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chronic heart failure; Renal failure
Most Recent Events
- 06 Apr 2022 Chong Kun Dang Pharmaceutical completes a phase I trial in Chronic heart failure (In volunteers) in South Korea (PO) (NCT05089279)
- 03 Nov 2021 Phase-I clinical trials in Chronic heart failure (In volunteers) in South Korea (PO) (NCT05089279)
- 22 Oct 2021 Chong Kun Dang Pharmaceutical plans a phase I trial in Chronic heart failure (In volunteers) in South Korea (PO) (NCT05089279)